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ABSTRACT 
Parkinson’s disease is characterized by the progressive loss of pigmented dopaminergic 
neurons in the substantia nigra and associated striatal deafferentation. Neuromelanin content 
is thought to reflect the loss of pigmented neurons, but available data characterising its 
relationship with striatal dopaminergic integrity are not comprehensive or consistent, and 
predominantly involve heterogeneous samples. In this cross-sectional study, we utilised 
neuromelanin-sensitive magnetic resonance imaging and the highly specific dopamine 
transporter positron emission tomography radioligand, 11C-PE2I, to assess the association 
between neuromelanin-containing cell levels in the substantia nigra pars compacta and 
nigrostriatal terminal density in vivo, in 30 patients with bilateral Parkinson’s disease. Fifteen 
healthy controls also underwent neuromelanin-sensitive imaging. We used a novel approach 
taking into account the anatomical and functional subdivision of substantia nigra into 
dorsal/ventral tiers and striatal nuclei into pre/post-commissural sub-regions, in accordance 
with previous animal and post-mortem studies, and consider the clinically asymmetric disease 
presentation. In vivo, Parkinson’s disease subjects displayed reduced neuromelanin levels in 
the ventral (-30±28%) and dorsal tiers (-21±24%) as compared to the control group (F1,43 = 
11.95, P = 0.001). Within the Parkinson’s disease group, nigral pigmentation was lower in the 
ventral tier as compared to the dorsal tier (F1,29 = 36.19, P < 0.001) and lower in the clinically-
defined most affected side (F1,29 = 4.85, P = 0.036). Similarly, lower dopamine transporter 
density was observed in the ventral tier (F1,29 = 76.39, P < 0.001) and clinically-defined most 
affected side (F1,29 = 4.21, P = 0.049). Despite similar patterns, regression analysis showed no 
significant association between nigral pigmentation and nigral dopamine transporter density. 
However, for the clinically-defined most affected side, significant relationships were observed 
between pigmentation of the ventral nigral tier with striatal dopamine transporter binding in 
pre-commissural and post-commissural striatal sub-regions known to receive nigrostriatal 
projections from this tier, while the dorsal tier correlated with striatal projection sites in the 
pre-commissural striatum (P < 0.05, Benjamini-Hochberg corrected). In contrast, there were 
no statistically significant relationships between these two measures in the clinically-defined 
least affected side. These findings provide important insights into the topography of 
nigrostriatal neurodegeneration in Parkinson’s disease, indicating that the characteristics of 
disease progression may fundamentally differ across hemispheres and support post-mortem 
data showing asynchrony in the loss of neuromelanin-containing versus tyrosine-hydroxylase 
positive nigral cells. 
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List of abbreviated terms: AC = anterior commissure; ADD = signal-averaged images; AI = 
asymmetry index; 11C-PE2I = ([11C]N-(3-iodopro-2E-enyl)-2β-carbomethoxy-3β-(4′-
methylphenyl)nortropane); CP = cerebral peduncle; CR = contrast ratio; DA = dopamine; 
DARTEL = diffeomorphic anatomical registration through exponentiated Lie algebra; DAT = 
dopamine transporter; HC = healthy control; FDR = false discovery rate; FSL = FMRIB 
software library; FWHM = full width at half maximum; GRAPPA = Generalized 
Autocalibrating Partial Parallel Acquisition; 123I-β-CIT = 2β-carbomethoxy-3β-
(4[123I]iodophenyl)tropane; 123I-FP-CIT = N-(3-Fluoropropyl)-2β-carbomethoxy-3β-(4-
[123I]iodophenyl)nortropane; LEDD = levodopa equivalent daily dose; MIAKAT = Molecular 
Imaging And Kinetic Analysis Toolbox; MNI = Montreal neurological institute; MPRAGE = 
Three-dimensional T1-weighted magnetization prepared rapid acquisition gradient echo; 
MPTP = 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 6-OHDA = 6-hydroxydopamine; PD 
= Parkinson’s disease; PC = posterior commissure; ROI = region of interest; SN = 
substantia nigra; SNc = substantia nigra pars compacta; SNcdor = substantia nigra pars 
compacta dorsal tier; SNcven = substantia nigra pars compacta ventral tier;  SNr = substantia 
nigra pars reticulata; SPECT = single-photon emission computed tomography; SPM = 
statistical parametric mapping; SRTM = simplified reference tissue model; TAC = time-
activity curve; TSE = turbo spin echo; UPDRS-III = Unified Parkinson’s disease rating scale 
part-III 
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INTRODUCTION 
The main pathological hallmarks of Parkinson’s disease consist of the progressive loss of 
pigmented dopaminergic (DA) neurons in the substantia nigra pars compacta (SNc) and a 
reduction of dopaminergic striatal afferents (Fearnley and Lees, 1991). An important factor in 
the disease aetiology concerns the function of neuromelanin that is contained within 
pigmented SNc neurons. Neuromelanin is a dark insoluble complex compound that is 
synthesised as a by-product of DA oxidation during cytosolic DA homeostasis. 
Physiologically, neuromelanin is proposed to have a dual role. It sequesters potentially toxic 
organic chemical, exogenous and endogenous metals such as iron in redox-inactive state 
while its synthesis confers neuroprotection from cytosolic reactive/toxic quinones. However, 
neuromelanin released into the extracellular space upon neuronal death, as is the case in 
Parkinson’s disease, further exacerbates neurodegeneration by releasing toxic metals and 
catecholaminergic products and inducing oxidative stress, local microglial activation and 
chronic inflammation (Zecca et al., 2006; Zucca et al., 2014; Zucca et al., 2017). 
 
Neuromelanin bound to metals such as iron and copper is highly paramagnetic, leading to T1-
shortening and hyperintense signal on T1-weighted turbo spin-echo magnetic resonance 
imaging (MRI) sequences (Sulzer et al., 2018). Hyperintensity in such images demonstrate 
direct associations with post-mortem neuromelanin-containing dopaminergic cell counts 
(Kitao et al., 2013). In recent years several studies evaluating nigral depigmentation have 
demonstrated the ability for neuromelanin-sensitive MR to distinguish between Parkinson’s 
disease and healthy individuals with high sensitivity and specificity, representing a potential -
in vivo index of neuromelanin content, disease progression and nigral cell death (Sasaki et al., 
2006; Kashihara et al., 2011; Schwarz et al., 2011; Matsuura et al., 2013; Ogisu et al., 2013; 
Ohtsuka et al., 2013; Castellanos et al., 2015; Reimao et al., 2015; Fabbri et al., 2017). 
 
Overall estimations suggest that ~30% of neuromelanin-containing cells in the SNc are lost 
prior to the appearance of classical Parkinson’s disease motor symptoms (Fearnley and Lees, 
1991; Cheng et al., 2010). In contrast, depletion of dopaminergic terminal markers in the 
principal projection sites of the striatum is in most cases much more pronounced at 
symptomatic threshold. Typically deficits of striatal DA integrity are estimated between 50-
80% as compared to controls, although lower values of ~20% have been reported 
(Bernheimer et al., 1973; Nyberg et al., 1983; Kish et al., 1988; Scherman et al., 1989; Lee et 
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al., 2000; Cheng et al., 2010). The difference between these estimates raises questions 
regarding the relationship between neuromelanin and the integrity of nigrostriatal terminals.  
 
To date, three studies have examined pigmented cell density in the SNc at post-mortem,  
alongside striatal dopamine transporter (DAT) binding measured in vivo with 123I-FP-CIT 
single-photon emission computed tomography at 2.5-5 years ante-mortem, but with 
conflicting results (Colloby et al., 2012; Kraemmer et al., 2014; Saari et al., 2017). Nigral cell 
counts were related to 123I-FP-CIT striatal specific binding ratios in Parkinson’s disease 
dementia (Colloby et al., 2012) and heterogeneous neurologic (Kraemmer et al., 2014) 
samples. This correlation was not present in a small group of 11 Parkinson’s disease patients 
(Saari et al., 2017), leading Saari and colleagues to hypothesise that the relationship between 
surviving nigral cells and striatal dopamine is lost in later stages of the disease. To our 
knowledge, only two recent studies have assessed this relationship in a multimodal setting. 
Using neuromelanin-sensitive MRI, strong positive correlations were demonstrated between 
striatal DAT binding and both SN volume, as well as the SN-to-cerebral peduncle contrast 
ratios, in cohorts with idiopathic Parkinson’s disease (Isaias et al., 2016) and mixed 
parkinsonism (Kuya et al., 2016). Despite these findings, the topography of the relationship 
between imaging biomarkers as it pertains to nigrostriatal damage has not yet been described 
in detail. 
 
In descriptive anatomy, neuronal tracing and staining studies define two cellular tiers of the 
SNc; a calbindin-positive dorsal tier which encompasses the ventral tegmental area (VTA) 
and a calbindin-negative ventral tier which spreads laterally toward the SN pars reticulata 
(SNr) (Lynd-Balta and Haber, 1994; Haber et al., 2000; Haber, 2014). In Parkinson’s disease, 
the pattern of nigral neuronal loss differs to normal ageing, exhibiting an exponential decay 
with approximately 45% reduction over the first decade of illness, beginning and most 
prominently affecting the lateral ventral tier before spreading to the medial ventral and dorsal 
tiers. This is at variance to the linear fallout observed in healthy ageing that is estimated at 
4.7-6% per decade and the relative sparing of the ventral compared to the dorsal tiers 
(Fearnley and Lees, 1991; Gibb and Lees, 1991). Meanwhile, the striatum is characterised by 
a rostrocaudal gradient of dopaminergic denervation with relative indemnity of caudate 
nucleus (Bernheimer et al., 1973; Nyberg et al., 1983; Kish et al., 1988; Scherman et al., 
1989; Lee et al., 2000; Cheng et al., 2010; Oh et al., 2012; Han et al., 2016). This Parkinson’s 
disease –related gradient is different to equivalent age-related declines of ~5-8% per decade 
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across the putamen and caudate in healthy individuals (Ishibashi et al., 2009; Shingai et al., 
2014). Evidence from animal work on nigrostriatal topography indicates that neurons 
originating in the SNc dorsal tier project predominantly to the head of the caudate and anterior 
putamen, while those of the ventral tier project to the posterior putamen and posterior caudate 
nuclei (Carpenter and Peter, 1972; Szabo, 1980; Lynd-Balta and Haber, 1994; Haber et al., 
2000; Haber, 2014).  
 
In this context, the current exploratory multimodal imaging study uses neuromelanin-sensitive 
MRI and PET with 11C-PE2I [a radioligand with high striatal binding (Jucaite et al., 2006) 
and substantially greater DAT specificity than 123I-FP-CIT or 123I-β-CIT (Abi-Dargham et al., 
1996; Emond et al., 1997; Guilloteau et al., 1998) that is highly correlated with Parkinson’s 
disease symptom severity (Li et al., 2018)] to examine the association between deficits in 
neuromelanin content in the SNc and reductions in DAT density in a Parkinson’s disease 
cohort with bilateral disease. Importantly, we take into account the distinct anatomical sub-
regions of both the SNc and the striatum, the reported topography of their neuronal 
connections and the lateralisation of clinical presentation, aiming to describe more 
comprehensively the association between the two imaging markers in vivo using an 
exploratory approach. While we expected there to be a relationship between neuromelanin 
and DAT density, based on available data, no specific hypotheses regarding its topography or 
extent were made. 
 
MATERIALS AND METHODS 
Subjects 
A total of thirty non-demented mild-moderate stage Parkinson’s disease patients and fifteen 
healthy controls were recruited from specialist movement disorder clinics and local 
advertisement respectively, under the TRANSEURO (http://www.transeuro.org.uk/) and 
PaMIR (Parkinson MRI Imaging Repository) research projects. Diagnosis of Parkinson’s 
disease was performed by movement disorder specialists in accordance with the Parkinson’s 
UK Brain Bank Criteria (Hughes et al., 1992), excluding atypical parkinsonism, concomitant 
vascular load, history of cognitive impairment, psychiatric disorders and factors that would 
preclude MRI scanning.  
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Patients were instructed to withdraw from all standard release anti-Parkinson’s disease 
medications 24 hours prior to motor and imaging assessments and 48 hours for prolonged 
release medications. This included levodopa, dopamine agonists, catechol-o-
methyltransferase and monoamine oxidase-B inhibitors. Caffeine in any form was not 
permitted within 12 hours prior to scan. Levodopa equivalent daily dosage (LEDD) for each 
participant was calculated (Tomlinson et al., 2010). 
 
The Movement Disorders Society Unified Parkinson’s Disease Rating Scale Part-III 
(UPDRS-III) (Goetz et al., 2008) administered by two experienced raters was used to 
calculate total motor severity in the practically-defined OFF-medicated state and sub-divided 
into bradykinesia (items 4-8, 14), rigidity (item 3), tremor (items 15-18) and axial (items 1-2, 
9-13) sub-scores. Clinical laterality was established based on clinical history recorded by the 
neurology unit at which patients were diagnosed. Asymmetry was also evaluated at research 
appointments during the study, derived from the sum of the UPDRS-III laterality items in the 
practically-defined OFF-medicated state.  
 
Ethical approval was obtained from the local Research Ethics Committees for TRANSEURO 
(IRAS: 57821, 65071, 78574; EPN2013/758, IK2013/685) and PaMIR (IRAS: 124223). 
Participant consent was obtained in writing in accordance with the Declaration of Helsinki.  
 
Image acquisition 
All scans were conducted at Invicro LLC (Hammersmith Hospital, London). 
Magnetic resonance imaging  
MRI scans were acquired for all Parkinson’s disease and healthy control participants on a 3T 
Siemens Magnetom Trio system with 32-channel head coil and consisted of neuromelanin-
sensitive T1-weighted turbo spin-echo (TSE: TR=829ms; TE=12ms; flip angle=123°; echo 
train length=4; echo spacing=11.5ms; low specific absorption rate; FoV=256*256mm; matrix 
size=320*320) and high-resolution volumetric T1-weighted magnetization prepared rapid 
acquisition gradient echo (MPRAGE: TR=2300ms; TE=2.98ms; flip angle=9°; time to 
inversion=900ms; GRAPPA acceleration factor PE=2; FoV=240*256mm; Matrix 
size=240*256) sequences.  
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For the MPRAGE, one whole brain volume was acquired consisting of 160 contiguous slices 
of 1mm thickness. For the TSE, 12 slices of 2.5mm thickness and slice gap of 0.25mm were 
acquired parallel to the AC-PC line with coverage of the whole midbrain and upper pons. 
Scans lasted 301 and 332 seconds respectively and patients were instructed to remain as still 
as possible for the duration.  
 
Positron emission tomography 
Parkinson’s disease participants (n=30) underwent 11C-PE2I ([11C]N-(3-iodopro-2E-enyl)-2β-
carbomethoxy-3β-(4′-methylphenyl)nortropane) PET scans, acquired on a Siemens Biograph 
TruePoint HI-REZ 6 PET/CT system. Patients were positioned supine such that the transaxial 
plane was parallel to the AC-PC plane and movement minimised using memory foam padding 
and video monitoring to aid repositioning. 11C-PE2I tracer volumes were prepared to 10ml 
using saline solution and administered intravenously as a single bolus injection followed 
immediately by 10ml saline flush (Injected dose=325.85±35.24 MBq; Injected 
mass=3.99±1.89 μg). Administration was at a rate of 1ml/s.  
 
Dynamic emission data were acquired continuously while patients were at rest for 90 minutes 
post-injection. Data were binned into a dynamic series of 26 temporal frames (8x15s, 3x60s, 
5x120s, 5x300s, 5x600s) and reconstructed with corrections for decay, scatter and attenuation 
using a filtered back-projection algorithm (direct inversion Fourier transform) with a matrix 
size of 128x128, zoom of 2.6 and 2mm isotropic pixel size and smoothed using a three-
dimensional 5mm FWHM trans-axial Gaussian image filter. A low-dose CT transmission 
scan (0.36mSv) was acquired for attenuation and scatter correction 
 
Image processing and region of interest analysis 
Neuromelanin-sensitive magnetic resonance imaging  
For the quantitative evaluation of neuromelanin-sensitive MRI scans, study-specific templates 
were first created using grey and white matter MPRAGE segmentations from both 
Parkinson’s disease and healthy control participants and diffeomorphic anatomical 
registration through exponentiated Lie algebra (DARTEL) in SPM12. Software defaults were 
modified to enable template and MPRAGE-to-template warp field generation in native voxel 
size (1mm3). Neuromelanin-sensitive T1-weighted images were co-registered to the 
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corresponding MPRAGE and DARTEL warp fields applied in one step to normalise all 
images to common space. The neuromelanin template could then be generated through voxel-
wise averaging (mean) over the entire cohort (n=45).  
 
Mesencephalic regions of interest (ROI) for the left/right substantia nigra pars compacta 
(SNc) were manually defined on five contiguous axial slices of the neuromelanin template on 
which the neuromelanin-related hyperintensity of the SNc was visible, at the level of the red 
nucleus and the inferior colliculus, in FSL (Jenkinson et al., 2012). The volume of the SNc on 
each axial slice was divided into two sections representing the ventral (SNcven) and dorsal 
(SNcdor) tiers, in accordance with post-mortem histological investigations on the spatial 
distribution of dopamine neurons relating to the striatal afferences of the SNc (Lynd-Balta and 
Haber, 1994; Haber et al., 2000; Haber, 2014). The decussation of the superior cerebral 
peduncle (CP) was also defined on the same axial slices as a reference region (Fig. 1). Once 
all ROIs were delineated the inverse DARTEL warp fields for each participant were applied 
to generate individualised ROIs for sampling in native space. This was performed in order to 
reduce the effect of warping/normalisation on the absolute voxel intensities within the images. 
Registration was checked visually in FSL before extracting mean ROI intensity values using 
the fslmeants command. Neuromelanin contrast ratios (CR) were calculated in accordance 
with Sasaki and colleagues (Sasaki et al., 2006) using the formula (SNc-CP)/CP for ventral 
and dorsal tiers separately. Contrast ratios were first calculated for the most/least affected 
sides for each ROI before averaging across sides to yield bilateral regional CRs. Contrast 
ratios of the whole SNc i.e. SNcven and SNcdor combined (SNccom) were also calculated. 
 
11C-PE2I positron emission tomography 
Pre-processing and kinetic modelling for MPRAGE and 11C-PE2I PET was conducted using 
MIAKAT™ v3.4.2. (Molecular Imaging and Kinetic Analysis Toolbox, Imanova Imaging 
Centre, London, UK) (Gunn et al., 2016), which utilises FSL (FMRIB Image Analysis Group, 
Oxford, UK) (Jenkinson et al., 2012), SPM (Statistical Parametric Mapping, Wellcome Trust 
Centre for Neuroimaging, London, UK) and in-house pre-processing and kinetic modelling 
procedures within an integrated PET analytical framework and is implemented in MATLAB® 
(Mathworks, Natick, MA, USA). 
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First, MPRAGE images were brain extracted, segmented and rigid-body registered to the 
Montreal Neurological Institute (MNI) template (Mazziotta et al., 1995). MPRAGE images in 
“pseudo-MNI” space (MPRAGEREG) were then used for manual subcortical ROI delineation 
in Analyze11.0. Afferent striatal dopaminergic connections from mesencephalic neurons 
show a distinctive dorsal-ventral pattern. The nigral dorsal tier projects to the ventromedial 
striatum while the ventral tier projects to the central associative and dorsal striatum (Lynd-
Balta and Haber, 1994; Haber et al., 2000; Haber, 2014). Striatal dub-division was conducted 
in accordance with the anatomical-landmark-based methods derived from work on the in vivo 
distribution of D3 receptors using 11C-(+)-PHNO (Tziortzi et al., 2011). In brief, the putamen 
was sub-divided into 3 sections on the axial plane; posterior to the AC (post-commissural 
putamen), anterior to the AC and dorsal to the posterior commissure (pre-commissural dorsal 
putamen), anterior to the AC and ventral to the posterior commissure (pre-commissural 
ventral putamen). The caudate was sub-divided into two sections on the axial plane; anterior 
to the AC (pre-commissural caudate) and posterior to the AC (post-commissural caudate) 
(Fig. 1A, Fig. 1B). ROIs of the whole putamen and caudate nucleus were formed by merging 
pre-commissural and post-commissural sub-divisions of the putamen and caudate 
respectively. Furthermore, the striatum was defined as the combination of the putamen and 
caudate nucleus. Cerebellar grey matter was automatically defined by applying the 
deformation fields estimated from the spatial normalisation (12-parameter affine 
transformation followed by non-linear warp) of the MNI template to the MPRAGEREG, to an 
MNI-based regional atlas (CIC Atlas v1.2.). Grey matter segmentation maps were then 
applied to isolate cerebellar grey matter. ROIs for the SNcven and SNcdor, which were defined 
on the study-specific template as described in the previous section, were also brought into 
MPRAGEREG space by applying the inverse DARTEL warp fields and rigid-body registration 
parameters (native-to-pseudo-MNI) in one step. 
 
Motion correction was conducted on the dynamic PET data to correct for intra-scan head 
movement using frame-to-frame rigid registration with the 16th frame (corresponding to 780-
900 seconds post-injection) as a reference, chosen due to high signal-to-noise ratio. No image 
artefacts due to substantial head movement were observed for any of the patients included in 
this study. Realigned frames corresponding to 10-90 minutes were subsequently summed to 
obtain signal-averaged (ADD) images that were then co-registered to the subjects 
MPRAGEREG using normalised mutual information as the cost function. The derived 
registration parameters were applied to bring the dynamic PET data into alignment with the 
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MPRAGEREG and corresponding ROI map. PET image processing was evaluated at each step 
before ROI maps were applied to the dynamic PET frames to generate regional time-activity 
curves (TACs) for all ROIs on the most and least affected sides separately as well as 
bilaterally. The simplified reference tissue model (SRTM) (Lammertsma and Hume, 1996) 
was used to calculate regional non-displaceable binding potential (BPND). Cerebellar grey 
matter was used as a reference as previous studies have demonstrated negligible tracer uptake 
in this region (Hall et al., 1999; Halldin et al., 2003; Jucaite et al., 2006). 
 
Registered frames between 10-90 minutes were subsequently summed to obtain signal-
averaged (ADD) images that were co-registered to the subjects MPRAGEREG using 
normalised mutual information as a cost function. Approximated co-registration matrices 
were then applied to both ADD images and realigned dynamic frames so that all images were 
in register with the subject MPRAGEREG and the corresponding ROI map. 
 
< Fig. 1 > 
 
Statistical analysis 
All statistical analyses were performed using R version 3.4.3 (R Core Team, 2017) and 
packages “afex” (Singmann et al., 2017), “emmeans” (Lenth, 2018) and “Hmisc” (Harrell Jr, 
2017). 
 
Demographic data were compared between Parkinson’s disease and healthy control groups 
using independent t-tests and Fisher’s exact test.  
 
To assess differences in neuromelanin CRs between groups and regions of the SNc, a mixed 
analysis of variance (ANOVA) was conducted with group (Parkinson’s disease, healthy 
control) as the between-subjects factor and region (bilateral SNcven, bilateral SNcdor) as the 
within-subjects factor.  
 
To assess lateralisation of SNc neuromelanin content, CR asymmetry indices (AI) (Seibyl et 
al., 1995) were calculated for the SNcven and SNcdor according to clinical laterality in the 
Parkinson’s disease group (most/least affected) and right/left in the healthy control group and 
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compared using one-tailed independent t-tests. Within the Parkinson’s disease group, 
lateralisation was assessed for both SNc neuromelanin content and DAT density using 2-way 
repeated measures ANOVA, with neuromelanin CR or 11C-PE2I BPND as the dependent 
variable and region (SNcven, SNcdor) and side (most/least affected) as within-subjects factors. 
 
Linear relationships between neuromelanin CRs in the SNc and 11C-PE2I BPND values in the 
striatum were tested using simple linear regression. Not all regional combinations between 
SNc and striatum were assessed; instead, planned tests were performed based on previous 
anatomical work mapping connectivity between sub-regions of the substantia nigra and 
striatum (Lynd-Balta and Haber, 1994; Haber et al., 2000; Haber, 2014). As such, regression 
analyses were conducted between neuromelanin CR (independent variable) in the SNcven (Fig. 
1, C7) and 11C-PE2I BPND (dependent variable) in the precommissural dorsal putamen and 
caudate (Fig. 1, A2-3) as well as the post-commissural putamen and caudate (Fig. 1, B4-5); 
and between neuromelanin CR in the SNcdor (Fig. 1, C6) and 11C-PE2I BPND in the pre-
commissural ventral putamen, dorsal putamen and caudate (Fig. 1, A1-3). Regression 
analyses were also conducted between neuromelanin CR and 11C-PE2I BPND values within 
the SNcven and SNc
dor. Analyses were performed for the most and least affected sides 
separately.  
 
Pearson’s product moment correlation coefficient (one-tailed) was used to explore 
relationships between each measure of disease severity (disease duration, UPDRS-III 
subscores; bradykinesia, rigidity, tremor, axial) and neuromelanin CRs for bilateral nigral 
regions (SNcven, SNcdor) as well as 11C-PE2I BPND for bilateral nigral and striatal sub-regions 
(SNcven, SNcdor, pre-commissural dorsal putamen, pre-commissural ventral putamen, pre-
commissural caudate, post-commissural putamen and post-commissural caudate). 
 
The Benjamini-Hochberg procedure was used to control the false-discovery rate (FDR) across 
all planned correlation and regression analyses simultaneously, at a desired threshold of P < 
0.05.  
 
Normal distribution was assessed graphically using normal probability plots as appropriate, 
extreme values were evaluated using Z-scores, boxplots and studentized residuals, 
independence of observations using Durbin-Watson statistic and homoscedasticity assessed 
by residual plots and Levene’s test. 
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Data Availability 
The authors confirm that data presented in this article is original. The data that support the 
findings of this study are available from the corresponding author, upon reasonable request. 
 
RESULTS 
Demographics 
Clinical and demographic characteristics for the Parkinson’s disease and healthy control 
groups are summarized in Table 1. There were no significant differences in age or gender 
between groups.  
 
< Table 1 > 
 
Neuromelanin in the substantia nigra in Parkinson’s disease compared to healthy 
controls  
Mixed ANOVA showed a main effect of group (F1,43=11.95, P=0.001), in which 
neuromelanin CRs were significantly lower in Parkinson’s disease (MeanEM=0.095, 95% CI 
[0.081, 0.109]) as compared to the healthy controls (MeanEM=0.129, 95% CI [0.115, 0.143]). 
There was also a main effect of region (F1,43=41.35, P < 0.001) whereby SNc
ven 
(MeanEM=0.100, 95% CI [0.090, 0.110]) showed significantly lower neuromelanin CRs than 
SNcdor (MeanEM=0.124, 95% CI [0.114, 0.134]). However, no significant group by region 
interaction was detected (F1,43=0.71, P=0.404) (Fig. 2). Including age and gender as 
covariates did not alter results. 
 
< Fig. 2 > 
 
Lateralisation of neuromelanin and dopamine transporters in Parkinson’s disease 
Asymmetry indices showed no significant differences between Parkinson’s disease and 
healthy control groups for SNcven (t43=0.75, P=0.230) or SNc
dor
 (t43=1.42, P=0.081). Removal 
of one extreme outlier (Table 2) did not alter results.  
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Two-way repeated measures ANOVA conducted on the Parkinson’s disease group revealed 
no significant interaction between region (SNcven, SNcdor) and side (most/least affected) on 
either neuromelanin CR (F1,29=0.17, P=0.685) (Fig. 3, A) or 
11C-PE2I BPND (F1,29=0.34, 
P=0.563) (Fig. 3, B). However, for neuromelanin CR, there was a marginally significant main 
effect of side (F1,29=4.85, P=0.036), whereby neuromelanin CR was lower in the most 
affected hemisphere (Mean=0.097, 95% CI [0.084, 0.109]) than in the least affected 
hemisphere (Mean=0.104, 95% CI [0.092, 0.117]), and a main effect of region (F1,29=36.19, 
P<0.001) in which SNcven (Mean=0.087, 95% CI [0.074, 0.100]) was significantly lower than 
SNcdor (Mean=0.114, 95% CI [0.101, 0.127]). Similarly for 11C-PE2I BPND, there was a 
marginally significant main effect of side (F1,29=4.21, P=0.049), in which 
11C-PE2I BPND was 
lower in the most affected hemisphere (Mean=0.633, 95% CI [0.584, 0.684]) than in the least 
affected hemisphere (Mean=0.667, 95% CI [0.618, 0.717]), and a main effect of region 
(F1,29=76.39, P<0.001), whereby SNc
ven (Mean=0.607, 95% CI [0.558, 0.655]) was 
significantly lower than SNcdor (Mean=0.694, 95% CI [0.646, 0.743]). Including age and 
gender as covariates did not alter results. 
 
< Fig. 3 > 
 
In terms of percentage of regional neuromelanin CR reduction, the Parkinson’s disease group 
showed a ventro-dorsal pattern of neurodegeneration as compared to healthy controls as 
follows SNcven (-30.03%) > SNcdor (-21.45%) (Table 2). 
 
< Table 2 > 
 
Relationship between neuromelanin and DAT density in the nigrostriatal system 
On the most affected side, significant positive relationships were found between 
neuromelanin CR in the SNcven and 11C-PE2I BPND in the pre-commissural dorsal putamen 
(F1,28=13.82, P=0.001) and caudate (F1,28=15.13, P=0.001) and the post-commissural 
putamen (F1,28=13.05, P=0.001) (Fig. 4). Neuromelanin CR in the SNc
dor was positively 
associated with 11C-PE2I BPND in the pre-commissural dorsal putamen (F1,28=7.99, P=0.009), 
and caudate (F1,28=23.12, P<0.001) (Fig. 5). Trends were found between neuromelanin CR in 
the SNcven and 11C-PE2I BPND in the post-commissural caudate (F1,28=5.13, P=0.031) and 
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between neuromelanin CR in the SNcdor and 11C-PE2I BPND in the pre-commissural ventral 
putamen (F1,28=5.22, P=0.030), however, after Benjamini-Hochberg FDR correction across 
all correlational tests, these results did not remain significant. Inclusion of additional 
covariates age and gender in the above regression models had only minimal impact upon the 
beta coefficients associated with the main independent variable (difference of 3.96±2.92%) 
and did not result in changes to significance level. No significant relationship was found 
between neuromelanin CR and 11C-PE2I BPND within either SNc
ven or SNcdor (Fig. 4, Fig. 5). 
 
On the clinically least affected side, there were no significant relationships between 
neuromelanin CR and 11C-PE2I BPND within the ventral or dorsal SNc or with 
11C-PE2I BPND 
in striatal sub-regions (Fig. 4, Fig. 5). 
 
< Fig. 4 > 
 
< Fig. 5 > 
 
Relationship between clinical severity and neuromelanin and DAT density 
SNc neuromelanin CR was inversely related to disease duration, particularly within the 
ventral tier, while no association with UPDRS-III bradykinesia, rigidity or axial subscales was 
evident. In contrast, SNc 11C-PE2I BPND appeared to show an opposing pattern whereby 
negative correlations were evident with UPDRS-III bradykinesia, rigidity or axial subscales 
but not disease duration. In the striatum, 11C-PE2I BPND appeared to correlate relatively 
consistently with both disease duration and UPDRS-III bradykinesia, rigidity and axial 
subscales. No significant correlations were found between UPDRS-III tremor and any 
imaging measure (Fig. 6). 
 
< Fig. 6 > 
 
DISCUSSION 
Neuromelanin loss in the substantia nigra 
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The present study assessed the integrity of nigrostriatal pathways in vivo in a moderate-stage 
Parkinson’s disease cohort by using neuromelanin-sensitive MR imaging and 11C-PE2I PET. 
As expected, Parkinson’s disease subjects had reduced neuromelanin when compared to 
controls, in line with previous investigations. While Sasaki et al. (2006) in their seminal paper 
examining neuromelanin in vivo report contrast ratio values almost double to what is reported 
here, our data show a larger effect size in equivalent tests (d = 1.1 and 0.8), with both studies 
having similar sensitivity to detect d > 0.8 with 80% power at α of 0.05. The disparity could 
be due to disease severity with the current cohort at 6.8 years of illness as compared to 2.5 
years, or to the size and placement of regions-of-interest. The size of the circular cursors used 
for sampling by Sasaki et al. (2006) was not detailed, though they state that pixels in the high 
signal intensity areas were measured. In contrast, the semi-automated sampling method used 
here was not as influenced by the local hyperintensity in individual subjects. In addition, our 
cohort was ~15 years younger.  
 
Relationship between nigral neuromelanin and striatal dopamine transporters  
Our findings demonstrate that the relationship between nigral neuromelanin and striatal DAT 
in Parkinson’s disease exhibits a remarkably lateralised pattern between the most and least 
affected brain hemispheres. Moderate to strong linear associations between the two measures 
were detected across the two regions but only in the most affected side. It is possible this 
lateralisation could be explained by ceiling effects and/or hemispheric lagging akin to that 
which has been observed in Parkinson’s disease with striatal dopaminergic markers such as 
aromatic ʟ-amino acid decarboxylase, vesicular monoamine transporter (type 2) and 
dopamine transporter (Lee et al., 2000; Nandhagopal et al., 2009). However, this alone seems 
unlikely given that significant depigmentation was found in both sides of the nigra, indicating 
that the neurodegenerative process in the least affected hemisphere had already begun in our 
cohort. If we assume that the neurodegenerative process occurs in a similar manner for both 
hemispheres, we might expect some degree of correlation between the two imaging measures 
on the least affected side, especially between regions with substantial SNc cell and striatal 
DAT loss. That this was not the case may be strong evidence to the contrary.  
 
Alternatively, these measures might reflect different aspects of disease progression. In a 
comprehensive post-mortem investigation, Kordower and colleagues recently observed that 
loss of melanin-containing neurons in the SNc was consistently outweighed by  loss of 
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tyrosine hydroxylase-positive neurons in the first two decades of illness (Kordower et al., 
2013). Thus while DAT imaging may yield markers reflecting dopaminergic phenotype and 
neuronal dysfunction, neuromelanin markers may relate more closely to structure and 
neurodegeneration. It is possible this may explain why here, DAT tended to correlate with 
bradykinetic/rigid/axial severity while nigral neuromelanin correlated with disease duration, 
particularly within the nigra. Interestingly, these differential trajectories appear to converge 
and become less variable over time (Kordower et al., 2013). It is feasible that this could 
account for the lateralisation demonstrated here, where associations become apparent only 
when the extent of nigral neuromelanin loss comes in line with that of tyrosine hydroxylase-
positive cell density.  
 
Relationship between neuromelanin and dopamine transporters within the 
substantia nigra 
In line with evidence from post-mortem data, Parkinson’s disease subjects displayed a ventral 
to dorsal pattern of nigral depigmentation (Fearnley and Lees, 1991; Gibb and Lees, 1991; 
Kordower et al., 2013) and showed a tendency for greater loss in the clinically-defined most 
affected side. Despite DAT density following a similar pattern of distribution we did not 
observe any relationship between the two imaging markers.  Similar results have also been 
shown in a small cohort of young healthy males (Ito et al., 2017). Recent nuclear imaging 
studies using 11C-FeCIT and 18F-FE-PE2I PET in early and de novo patients have shown that 
the loss of DAT in the striatum (-35-70%) exceeds the loss in the substantia nigra (-25-30%), 
as compared to healthy controls (Caminiti et al., 2017; Fazio et al., 2018). One explanation 
for this relates to evidence suggesting that distal axonal degeneration occurs initially before 
proceeding retrograde towards the cell body (Calo et al., 2016; Kurowska et al., 2016; 
Tagliaferro and Burke, 2016). If this is the case then the relatively modest DAT loss in the 
nigra may represent delayed, slower or variable progression rate to that in the striatum. While 
this is yet to be studied, it could explain why the relationship with DAT differs between the 
nigra and striatum. 
 
Comparison with previous studies 
A few studies (Colloby et al., 2012; Kraemmer et al., 2014; Saari et al., 2017) have evaluated 
the relationship between nigral neuromelanin and striatal DAT, using ante-mortem DAT–
specific SPECT (123I-FP-CIT or 123I-β-CIT) with either post-mortem histochemistry of the 
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SNc (conducted ~2.5-5 years after SPECT assessment) or neuromelanin-sensitive MRI. 
Positive correlations have been noted in a mixed dementia cohorts (Colloby et al., 2012) and 
in general neurological samples(Kraemmer et al., 2014; Kuya et al., 2016) and were in line 
with those found in smaller Parkinson’s disease samples (Isaias et al., 2016) and in the current 
Parkinson’s disease-only cohort.  
 
In contrast, Saari and colleagues found no significant correlations between nigral 
neuromelanin and striatal DAT in a small group of 11 Parkinson’s disease and 7 individuals 
with mixed parkinsonism (Saari et al., 2017). This may have been due to lack of power and/or 
inclusion of mixed parkinsonism, as correlation coefficients appear to graduate from 
zero/weak to moderate upon removal of non-Parkinson’s disease patients from the analysis. 
The authors suggested that the relationship between nigral neuromelanin cell density and 
striatal DAT may dissipate as the disease progresses. Indeed, while results showing that nigral 
neuronal density in a mixed dementia cohort accounts for 58%, 40% and 20% of the variance 
in posterior and anterior putamen and caudate DAT respectively, they appear to be driven 
mostly by non-Parkinson’s disease individuals (Colloby et al., 2012), with the Parkinson’s 
disease dementia data tending towards an asymptote. In the current Parkinson’s disease 
cohort, although significant relationships were found between both tiers of the nigra and their 
striatal afferents in the most affected side, it appeared that this association was strongest 
between the dorsal tier and pre-commissural caudate, which retains the highest DAT 
expression across the striatum (Nandhagopal et al., 2009; Oh et al., 2012; Han et al., 2016). 
However, normative data from a group of healthy young men show that nigral neuromelanin 
accumulation does not correlate with nigral DAT at baseline (Ito et al., 2017). In addition, 
preclinical work demonstrates correlations in more pathologically advanced 6-OHDA mouse 
models but not in mild MPTP regimes (Alvarez-Fischer et al., 2007). Thus, it is possible that 
the relationship between nigral neuromelanin content and striatal DAT is constrained by both 
ceiling and floor effects and may be evident only at some stages of Parkinson’s disease 
progression.  
 
Isaias and colleagues found no relationship between neuromelanin and DAT asymmetries, 
performing analyses on the whole nigra, putamen and caudate (Isaias et al., 2016). Moreover, 
correlational analyses of absolute values involved collapsing across the most/least affected 
sides. Others have found positive results but using asymmetry indices calculated between left 
and right hemispheres (Kraemmer et al., 2014; Kuya et al., 2016), thus limiting pathological 
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relevance and interpretability. The only study to perform correlations separately for most/least 
affected sides showed significant associations between asymmetry indices but no correlations 
of absolute values (Saari et al., 2017). Importantly however, these authors distinguished 
most/least affected sides as those with higher/lower cell count and/or DAT density. In the 
present study, while we found greater demelanisation in the clinically most affected side we 
also noted that a significant proportion of our patients (~38%) displayed the opposite i.e. 
greater neuromelanin loss in the clinically least affected side, which was discordant to the side 
with greatest DAT loss. This finding has been discussed recently (Isaias et al., 2016) and 
possibly stands as an important methodological factor to explain the discordance between 
results.  
 
Limitations and considerations 
There are some limitations in the current report. Delineation of the SNc was based on the 
hyperintense area of the midbrain on neuromelanin MR images as it is not easily visible on 
standard structural scans, which could introduce bias towards overall greater values. We 
attempted to resolve this by employing an automated procedure in which the SNc was 
delineated on neuromelanin templates created via normalisation of structural scans from both 
Parkinson’s disease and healthy control groups. In doing so, we were able to remain objective 
and consistent across individuals. Moreover, our data correspond well with percentage losses 
in a less advanced subset of 9 patients (1-14 year disease duration, Mean = 8 years) from 
Kordower and colleagues (Kordower et al., 2013), whose values indicate ~22% loss in the 
dorsal and ~35% in the ventral tiers. Second, while striatal regions of interest were defined 
according to anatomical-landmark-based guidelines derived from a recent study on in vivo 
distribution of D3 receptors, parcellation could potentially be improved using connectivity-
based methods such as probabilistic tractography (Chowdhury et al., 2013). Age and gender 
have recently been shown to have significant effects over neuromelanin levels in healthy 
individuals (Xing et al., 2018). While we attempted to account for this through addition of 
covariates in our analyses, this constitutes incomplete control and thus the influence of these 
variables should be considered here and in future work. In addition, although striatal DAT in 
Parkinson’s disease is well characterised using mostly SPECT ligands such as 123I-FP-CIT, 
we did not obtain 11C-PE2I scans for healthy controls. This would have enabled parallel 
analysis from which we could ascertain the normative nigrostriatal state across both brain 
hemispheres using the two imaging markers. Lastly, it has been shown that chronic exposure 
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to dopaminergic drugs including levodopa and dopamine agonists can down-regulate striatal 
DAT to varying degrees (-4-7.2%), depending on the exposure dose (Guttman et al., 2001; 
Fahn et al., 2004). As such, chronic exposure should be considered as a confounding factor in 
the current study.   
 
Conclusions 
The current study provides important insights into the relationship between neuromelanin 
content in the SNc and striatal DAT density in moderate stage Parkinson’s disease, as 
measured in vivo using neuromelanin-sensitive MRI and 11C-PE2I PET. Reduction of nigral 
pigmentation in Parkinson’s disease displays an uneven pattern of association with the loss of 
striatal dopaminergic function towards the clinically most affected side while no relationship 
was found with nigral DAT. These findings may be indicative of a lag in disease progression 
or differences in the pathologic processes measured that could manifest with heterogeneous 
rate of decline, convergence and symmetry. However, further work including longitudinal 
imaging assessment on the demelanisation trajectories in the nigra, in both tiers and on the 
most and least affected side would provide a strong basis from which we could start to 
understand the relationship between these pathologic processes. 
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Figure 1: Region of interest definition in the substantia nigra and striatum. Bottom right 
is a sagittal midline view of a 3D T1-weighted MPRAGE template, derived using DARTEL 
with 30 Parkinson’s disease and 15 healthy control participants. The red line annotations 
illustrate the position of the coronal and axial planes corresponding to the sections depicted in 
panels A, B and C. Panels A and B represent 11C-PE2I ADD images overlaid onto the 
structural MPRAGEREG from two levels of the coronal plane either side of the anterior 
commissure along the y-axis.  Regions of the pre-commissural striatum (Panel A) consist of 
ventral putamen (1 - red), dorsal putamen (2 - green) and caudate (3 - purple). Regions of the 
post-commissural striatum (Panel B) include putamen (4 - orange) and caudate (5 - blue). 
Panel C shows an axial slice of the neuromelanin-sensitive T1-weighted template derived 
using DARTEL (n = 45) at the level of the substantia nigra pars compacta, including 
delineation of the dorsal (6 - red) (SNcdor) and ventral (7 - blue) (SNcven) tiers, as well as 
cerebral peduncle (8 - yellow). Descriptive anatomy demonstrates projections from the dorsal 
tier (6) to striatal regions 1-3 while the ventral tier (7) projects to regions 2-5 (Lynd-Balta and 
Haber, 1994; Haber et al., 2000; Haber, 2014). MPRAGE = Three-dimensional T1-weighted 
magnetization prepared rapid acquisition gradient echo; ROI = region of interest; 11C-PE2I = 
([11C]N-(3-iodopro-2E-enyl)-2β-carbomethoxy-3β-(4′-methylphenyl)nortropane); ADD = 
signal-averaged images; SNcven = substantia nigra pars compacta ventral tier;  SNcdor = 
substantia nigra pars compacta dorsal tier. 
 
Figure 2: Neuromelanin loss in the ventral and dorsal tiers of the substantia nigra pars 
compacta in Parkinson’s disease as compared to healthy controls. Strip plot illustrating 
neuromelanin CR values for individuals of both Parkinson’s disease and healthy control 
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groups and for each sub-region of the substantia nigra pars compacta (ventral tier, dorsal tier). 
Solid black points represent individuals within the Parkinson’s disease group and hollow grey 
points represent individuals within the healthy control group. Crossbars represent 95% 
confidence intervals about the estimated marginal mean derived from the mixed ANOVA 
analysis. PD = Parkinson’s disease; HC = Healthy control; SNc = substantia nigra pars 
compacta; CR = neuromelanin contrast ratio. 
 
Figure 3: Lateralisation of neuromelanin loss and DAT density in the ventral and dorsal 
tiers of the substantia nigra pars compacta for the clinically-defined most and least 
affected sides. Strip plots showing neuromelanin CR (A) and 11C-PE2I BPND (B) values for 
individuals within the Parkinson’s disease group as a function of the clinically-defined 
most/least affected side and sub-region of the substantia nigra pars compacta (ventral tier, 
dorsal tier). Solid blue points represent the ventral tier while hollow red points represent the 
dorsal tier. Points between the clinically-defined most and least affected sides are connected 
with either a solid blue line (ventral tier) or dashed red line (dorsal tier) to illustrate 
asymmetry within individuals. Crossbars represent 95% confidence intervals about the mean. 
SNc = substantia nigra pars compacta; DAT = dopamine transporter; CR = neuromelanin 
contrast ratio; BPND = non-displaceable binding potential; 
11C-PE2I = ([11C]N-(3-iodopro-2E-
enyl)-2β-carbomethoxy-3β-(4′-methylphenyl)nortropane). 
 
Figure 4: Association between neuromelanin in the substantia nigra pars compacta 
ventral tier and nigrostriatal dopamine transporter binding. Scatterplots and simple 
linear regression showing positive relationships between neuromelanin CR in the SNcven and 
11C-PE2I BPND in the pre-commissural dorsal putamen (A), pre-commissural caudate (B), 
post-commissural putamen (C), post-commissural caudate (D) and SNcven (E) in the 
clinically-defined most affected (solid blue points, solid line) and least affected sides (hollow 
black points, dashed line). Grey shaded areas represent 95% confidence intervals. **indicates 
significant result following Benjamini-Hochberg FDR correction for all correlational tests. 
*indicates significance at P < 0.05. MA = most affected; LA = least affected; SNcven = 
substantia nigra pars compacta ventral tier; CR = neuromelanin contrast ratio; BPND = non-
displaceable binding potential; 11C-PE2I = ([11C]N-(3-iodopro-2E-enyl)-2β-carbomethoxy-
3β-(4′-methylphenyl)nortropane). 
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Figure 5: Association between neuromelanin in the substantia nigra pars compacta 
dorsal tier and nigrostriatal dopamine transporter binding. Scatterplots and simple linear 
regression showing positive relationships between neuromelanin CR in the SNcdor and 11C-
PE2I BPND in the pre-commissural dorsal putamen (A), pre-commissural ventral putamen (B), 
pre-commissural caudate (C) and SNcdor (D) in the clinically-defined most affected (solid red 
points, solid line) and least affected sides (hollow black points, dashed line). Grey shaded 
areas represent 95% confidence intervals. **indicates significant result following Benjamini-
Hochberg FDR correction for all correlational tests. *indicates significance at P < 0.05. MA = 
most affected; LA = least affected; SNcdor = substantia nigra pars compacta dorsal tier; CR = 
neuromelanin contrast ratio; BPND = non-displaceable binding potential; 
11C-PE2I = ([11C]N-
(3-iodopro-2E-enyl)-2β-carbomethoxy-3β-(4′-methylphenyl)nortropane). 
 
Figure 6: Relationship between measures of clinical severity and regional neuromelanin 
and dopamine transporter binding. Pearson’s correlation matrix with measures of clinical 
severity by row and neuromelanin CR in the SNc and 11C-PE2I BPND in the SNc and striatum 
by column. Tiles are colour coded and labelled with the value of the correlation coefficient. 
**indicates significant result following Benjamini-Hochberg FDR correction for all 
correlational tests. *indicates significance at P < 0.05. Pre-C = Pre-Commissural; Post-C = 
Post-Commissural; SNcdor = substantia nigra pars compacta dorsal tier; SNcven = substantia 
nigra pars compacta ventral tier; UPDRS-III = Unified Parkinson’s Disease Rating Scale Part 
III; BPND = non-displaceable binding potential; 
11C-PE2I = ([11C]N-(3-iodopro-2E-enyl)-2β-
carbomethoxy-3β-(4′-methylphenyl)nortropane).  
